Background

Background

The manufacturer of bevacizumab (Roche Products) was invited to submit evidence for this single technology appraisal in April 2007.

In June 2007, the manufacturer informed NICE that it would not be launching or promoting bevacizumab for the lung cancer indication and as a result it would not be making an evidence submission for this appraisal.

NICE has therefore terminated this single technology appraisal.

  • National Institute for Health and Care Excellence (NICE)